GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » Equity-to-Asset

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Equity-to-Asset : 0.81 (As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Dawnrays Pharmaceutical (Holdings)'s Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$3,518 Mil. Dawnrays Pharmaceutical (Holdings)'s Total Assets for the quarter that ended in Jun. 2024 was HK$4,354 Mil. Therefore, Dawnrays Pharmaceutical (Holdings)'s Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.81.

The historical rank and industry rank for Dawnrays Pharmaceutical (Holdings)'s Equity-to-Asset or its related term are showing as below:

HKSE:02348' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.71   Med: 0.78   Max: 0.87
Current: 0.83

During the past 13 years, the highest Equity to Asset Ratio of Dawnrays Pharmaceutical (Holdings) was 0.87. The lowest was 0.71. And the median was 0.78.

HKSE:02348's Equity-to-Asset is ranked better than
84.7% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs HKSE:02348: 0.83

Dawnrays Pharmaceutical (Holdings) Equity-to-Asset Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) Equity-to-Asset Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.71 0.72 0.79 0.83

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.79 0.79 0.81 0.83

Competitive Comparison of Dawnrays Pharmaceutical (Holdings)'s Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Dawnrays Pharmaceutical (Holdings)'s Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dawnrays Pharmaceutical (Holdings)'s Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dawnrays Pharmaceutical (Holdings)'s Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Dawnrays Pharmaceutical (Holdings)'s Equity-to-Asset falls into.


;
;

Dawnrays Pharmaceutical (Holdings) Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Dawnrays Pharmaceutical (Holdings)'s Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3122.362/3962.388
=0.79

Dawnrays Pharmaceutical (Holdings)'s Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=3518.132/4354.127
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Dawnrays Pharmaceutical (Holdings) Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Li Kei Ling
Hung Yung Lai
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Li Tung Ming
Fmr Llc 2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines